IP Library Granted Patent US 10,111,877
Granted Patent B2
US 10,111,877 · App. 15/444,077 · Granted Oct 30, 2018

Modulators of androgen synthesis

Inventors: Suzanne Dilly (Oxfordshire, GB); Gregory Stoloff (London, GB); Paul Taylor (London, GB)
Assignee: Tangent Reprofiling Limited
A61K31/519A61K31/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,111,877
App. No.
15/444,077
Granted
Oct 30, 2018
Kind
B2
Abstract

The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.

Claims (20)

1. A pharmaceutical composition comprising 0.1 mg to 20 mg of risperidone, 0.1 mg to 20 mg of a 9Z,11E conjugated Linoleic Acid, pharmaceutically-acceptable carriers and/or pharmaceutically-acceptable components, wherein there is a synergistic effect between the therapeutically effective amount of the risperidone and the therapeutically effective amount of a 9Z,11E conjugated Linoleic Acid; and wherein there is an inhibition in tumor growth in a cancer selected from the group consisting of pancreatic, prostate and lung cancer upon the administration of the pharmaceutical composition.

2. The pharmaceutical composition according to claim 1 , wherein the risperidone is in an amount of 0.5 mg to 15 mg.

3. The pharmaceutical composition according to claim 2 , wherein the risperidone is in an amount of 1 mg to 10 mg.

4. The pharmaceutical composition according to claim 3 , wherein the risperidone is in an amount of 1 mg to 5 mg.

5. The pharmaceutical composition according to claim 1 , wherein the 9Z,11E conjugated Linoleic Acid is in an amount of 0.5 mg to 15 mg.

6. The pharmaceutical composition according to claim 5 , wherein the 9Z,11E conjugated Linoleic Acid is in an amount of 1 mg to 10 mg.

7. The pharmaceutical composition according to claim 6 , wherein the 9Z,11E conjugated Linoleic Acid is in an amount of 1 mg to 5 mg.

8. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically-acceptable carriers include vehicles, stabilizers, diluents, additives, auxiliarys or excipients.

9. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically-acceptable components include buffers, preservatives, tonicity adjusters, salts, antioxidants, osmolality adjusting agents, physiological substances, pharmacological substances, bulking agents, emulsifying agents, wetting agents, flavoring agents, or coloring agents.

10. A pharmaceutical composition comprising 0.5 mg to 15 mg of risperidone, 0.5 mg to 15 mg of a 9Z,11E conjugated Linoleic Acid, pharmaceutically-acceptable carriers and/or pharmaceutically-acceptable components, wherein there is a synergistic effect between the therapeutically effective amount of the risperidone and the therapeutically effective amount of a 9Z,11E conjugated Linoleic Acid; and wherein there is an inhibition in tumor growth in a cancer selected from the group consisting of pancreatic, prostate and lung cancer upon the administration of the pharmaceutical composition.

11. The pharmaceutical composition according to claim 10 , wherein the risperidone is in an amount of 5 mg to 15 mg.

12. The pharmaceutical composition according to claim 11 , wherein the risperidone is in an amount of 5 mg to 10 mg.

13. The pharmaceutical composition according to claim 10 , wherein the risperidone is in an amount of 1 mg to 10 mg.

14. The pharmaceutical composition according to claim 13 , wherein the risperidone is in an amount of 1 mg to 5 mg.

15. The pharmaceutical composition according to claim 10 , wherein the 9Z,11E conjugated Linoleic Acid is in an amount of 5 mg to 15 mg.

16. The pharmaceutical composition according to claim 15 , wherein the 9Z,11E conjugated Linoleic Acid is in an amount of 5 mg to 10 mg.

17. The pharmaceutical composition according to claim 10 , wherein the 9Z,11E conjugated Linoleic Acid is in an amount of 1 mg to 10 mg.

18. The pharmaceutical composition according to claim 17 , wherein the 9Z,11E conjugated Linoleic Acid is in an amount of 1 mg to 5 mg.

19. The pharmaceutical composition according to claim 10 , wherein the pharmaceutically-acceptable carriers include vehicles, stabilizers, diluents, additives, auxiliarys or excipients, or any combination thereof.

20. The pharmaceutical composition according to claim 10 , wherein the pharmaceutically-acceptable components include buffers, preservatives, tonicity adjusters, salts, antioxidants, osmolality adjusting agents, physiological substances, pharmacological substances, bulking agents, emulsifying agents, thickening agents, wetting agents, flavoring agents, or coloring agents, or any combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2017
From: DILLY, SUZANNE; STOLOFF, GREGORY A.; TAYLOR, PAUL
To: TANGENT REPROFILING LIMITED
Reel/Frame 041564/0213 →
Continuity (7)
Continuation 15169610 · May 31, 2016
Continuation 14708052 · May 8, 2015
Continuation In Part 14037481 · Sep 26, 2013
Provisional Application 61705790 · Sep 26, 2012
Provisional Application 61871662 · Aug 29, 2013
Provisional Application 61990800 · May 9, 2014
Related Publication 20170165268A1 · Jun 15, 2017